Threefold Higher Risk for Breast Cancer Death With DCIS Threefold Higher Risk for Breast Cancer Death With DCIS
Compared to the general population, women with ductal carcinoma in situ (DCIS) were more than three times more likely to die from breast cancer; the risk was particularly high for Black women and young women.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 18, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Women with DCIS have 3x the risk of breast cancer death
A new study adds weight to the belief that ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Delayed breast cancer surgery not tied to worse outcomes Preop MRI finds 11% more cancer in women with DCIS Years later, DCIS tied to more imaging but not anxiety Black women still at higher risk of breast cancer death Does imaging modality influence DCIS recurrence? (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - September 17, 2020 Category: Radiology Source Type: news

Surgical Delays Not Life-Threatening in Early Breast Cancer
WEDNESDAY, Aug. 12, 2020 -- Surgical delays do not seem to be life-threatening for women with ductal carcinoma in situ (DCIS) or with early-stage estrogen receptor-positive (ER+) breast cancer, according to a study published online Aug. 6 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 12, 2020 Category: Pharmaceuticals Source Type: news

Carcinoma in Situ of the Bladder: Why Is It Underdetected? Carcinoma in Situ of the Bladder: Why Is It Underdetected?
The diagnosis of carcinoma in situ of the bladder remains challenging. Could certain new diagnostic techniques improve the detection rate?Current Opinion in Urology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 18, 2020 Category: Consumer Health News Tags: Urology Journal Article Source Type: news

Increased Risk for Invasive Breast Cancer After DCIS Increased Risk for Invasive Breast Cancer After DCIS
A new analysis shows that any diagnosis of ductal carcinoma in situ is associated with a long-term risk of invasive breast cancer and that treatment lowers this risk.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 5, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Very Early-Stage Breast Cancer Ups Long-Term Odds for Invasive Tumors: Study
FRIDAY, May 29, 2020 -- Women with cancerous cells in their milk ducts -- also known as DCIS -- are at a high risk for developing fatal breast cancer, British researchers report. DCIS is short for ductal carcinoma in situ, an early form of breast... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 29, 2020 Category: General Medicine Source Type: news

Trastuzumab achieves slight reduction in recurrence for women with HER2-positive DCIS
(NRG Oncology) The addition of the monoclonal antibody therapy Trastuzumab to radiotherapy did not reach the protocol objective of a 36% reduction in the ipsilateral breast tumor recurrence rate for women with HER2-positive ductal carcinoma in situ (DCIS) on the NRG Oncology clinical trial NSABP B-43. The trial did find a statistically non-significant, modest (19%) reduction in the rate of recurrence among women that received trastuzumab, but this difference was not statistically significant. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 29, 2020 Category: Cancer & Oncology Source Type: news

Risk for Later Invasive Breast Cancer Up for Women With DCIS
THURSDAY, May 28, 2020 -- Women with screening-detected ductal carcinoma in situ (DCIS) have increased long-term risks for invasive breast cancer and breast cancer death, according to a study published online May 27 in The BMJ. Gurdeep S. Mannu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 28, 2020 Category: Pharmaceuticals Source Type: news

How to Think About Your Cancer Care in the Time of COVID-19
Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment. Don’t panic. In the vast majority of cases, a diagnosis of cancer is not an emergency even though it feels like one. There is time to learn about your options and sort out what is right for you. For now, there will be changes to how we do things. Some of the changes will feel disruptive, but many will lead to better, more patient-centered care. Minimizing your chances of exposure to the virus doesn&rs...
Source: TIME: Health - April 28, 2020 Category: Consumer Health News Authors: Dr. Laura Esserman Tags: Uncategorized COVID-19 Source Type: news

Sporadic activation of an oxidative stress-dependent NRF2-p53 signaling network in breast epithelial spheroids and premalignancies
Breast and mammary epithelial cells experience different local environments during tissue development and tumorigenesis. Microenvironmental heterogeneity gives rise to distinct cell regulatory states whose identity and importance are just beginning to be appreciated. Cellular states diversify when clonal three-dimensional (3D) spheroids are cultured in basement membrane, and one such state is associated with stress tolerance and poor response to anticancer therapeutics. Here, we found that this state was jointly coordinated by the NRF2 and p53 pathways, which were costabilized by spontaneous oxidative stress within 3D cult...
Source: Signal Transduction Knowledge Environment - April 14, 2020 Category: Science Authors: Pereira, E. J., Burns, J. S., Lee, C. Y., Marohl, T., Calderon, D., Wang, L., Atkins, K. A., Wang, C.-C., Janes, K. A. Tags: STKE Research Articles Source Type: news

FDA Approves Pembrolizumab for BCG-Unresponsive NMIBC
The FDA   approved pembrolizumab (Keytruda) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Kevin Wright Source Type: news

FDA Approves Pembrolizumab for High-Risk Bladder Cancer FDA Approves Pembrolizumab for High-Risk Bladder Cancer
Pembrolizumab is now approved for patients with bacillus Calmette-Guerin -unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Pembrolizumab for Treatment of Certain Patients with NMIBC
The FDA approved pembrolizumab for the treatment of patients with BCG –unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in-situ with or without papillary tumors who are ineligible for or chose to not undergo cystectomy. (Source: CancerNetwork)
Source: CancerNetwork - January 8, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

RT for DCIS Ups Mortality Risk in Invasive Second Breast Cancer
FRIDAY, Dec. 20, 2019 -- For women with primary ductal carcinoma in situ (DCIS), use of radiotherapy (RT) is associated with increased rates of breast cancer-specific mortality for those women who subsequently develop an invasive second breast... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 20, 2019 Category: Pharmaceuticals Source Type: news

Patients with Invasive Secondary Breast Cancer May Have Higher Mortality
Patients who previously received radiotherapy for ductal carcinoma in situ may have higher mortality after developing an invasive second breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - December 3, 2019 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

New Study Suggests Women With Dense Breast Tissue May Benefit From Regular MRIs
While there has been some controversy over when women should start getting mammograms, all experts agree that screening is an important first step in detecting breast cancers and treating them early. But for some women, that’s not enough. For the approximately 40% of women with dense breast tissue, and especially the 10% with extremely dense tissue, cancer cells are harder to detect, since the denser tissue can mask small growths. In addition, dense breast tissue itself is also a risk factor for developing cancer. There’s been debate among experts over whether these women should have additional screening, on to...
Source: TIME: Health - November 27, 2019 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Breast Cancer embargoed study Research Source Type: news

Mesothelioma Death from 9/11 Signals Start of Things to Come
Malignant mesothelioma has become the latest deadly cancer linked directly to the rescue, recovery and cleanup efforts following the 9/11 terrorist attack on New York City in 2001. The long-running threat has come to fruition. Eighteen years after Manhattan was engulfed in the asbestos-laced, toxic cloud of dust — caused primarily by the World Trade Center destruction — the first death from pleural mesothelioma attributed to 9/11 has been recorded. Nick Ursta, 52, from the southwestern part of Pennsylvania, died after a year-long battle with the rare cancer. Ursta, a construction worker and fireman by trade, w...
Source: Asbestos and Mesothelioma News - November 14, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

No Benefit Seen for SLNB in BCS for DCIS in Older Women
THURSDAY, Oct. 31, 2019 -- For older patients with ductal carcinoma in situ (DCIS) who undergo breast-conserving surgery (BCS), sentinel lymph node biopsy (SLNB) is not associated with improvements in long-term outcomes, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2019 Category: Pharmaceuticals Source Type: news

Don't Delay Very Early-Stage Breast Cancer Surgery
Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma and a slightly lower survival rate, researchers found. (Source: WebMD Health)
Source: WebMD Health - October 25, 2019 Category: Consumer Health News Source Type: news

Delay of Surgery for DCIS Ups Risk for Invasive Breast Cancer
FRIDAY, Oct. 25, 2019 -- For each month of delay between diagnosis and surgery for ductal carcinoma in situ (DCIS), there is slightly worse survival and an increase in risk for invasive disease, according to a study published online Sept. 27 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 25, 2019 Category: Pharmaceuticals Source Type: news

In Older Women With DCIS, Skip Lymph Node Biopsy In Older Women With DCIS, Skip Lymph Node Biopsy
A new analysis shows that the extra step of performing lymph node biopsy has no benefits but may cause harm in older women with ductal carcinoma in situ (DCIS).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 24, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Don't Delay Surgery for Very Early-Stage Breast Cancer, Study Suggests
THURSDAY, Oct. 24, 2019 -- Delaying surgery for a noninvasive breast cancer can have dire consequences, a new study shows. Longer delays in surgery for ductal carcinoma in situ (DCIS) breast cancer lead to a higher risk of invasive ductal carcinoma... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - October 24, 2019 Category: General Medicine Source Type: news

AI Program May Aid in Pathologic Evaluation of Breast Biopsies
FRIDAY, Aug. 16, 2019 -- An artificial intelligence program outperforms pathologists for differentiating ductal carcinoma in situ (DCIS) from atypia, according to a study published online Aug. 9 in JAMA Network Open. Ezgi Mercan, Ph.D., from the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 16, 2019 Category: Pharmaceuticals Source Type: news

Artificial intelligence could yield more accurate breast cancer diagnoses
UCLA researchers have developed an artificial intelligence system that could help pathologists read biopsies more accurately and to better detect and diagnose breast cancer.The new system,described in a study published today in JAMA Network Open, helps interpret medical images used to diagnose breast cancer that can be difficult for the human eye to classify, and it does so nearly as accurately or better as experienced pathologists.“It is critical to get a correct diagnosis from the beginning so that we can guide patients to the most effective treatments,” said Dr. Joann Elmore, the study’s senior author ...
Source: UCLA Newsroom: Health Sciences - August 9, 2019 Category: Universities & Medical Training Source Type: news

Contrast ultrasound can tell DCIS from fibroadenomas
Contrast-enhanced ultrasound can distinguish ductal carcinoma in situ (DCIS)...Read more on AuntMinnie.comRelated Reading: Ultrasound options abound for diagnosing liver disease ICUS applauds payment changes for CEUS Contrast ultrasound helps characterize breast lesions Drop ultrasound contrast agent warning, society says Contrast US tops CT, MRI for classifying kidney tumors (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - June 19, 2019 Category: Radiology Source Type: news

Dr. Meyers on Low-Dose Tamoxifen vs Placebo After Surgery for DCIS Breast Cancer
Cancer Network spoke with Marleen Meyers, MD, about evidence on  low-dose tamoxifen vs placebo in women who had surgery for their ductal carcinoma in situ. (Source: CancerNetwork)
Source: CancerNetwork - June 17, 2019 Category: Cancer & Oncology Authors: Marleen Meyers, MD Source Type: news

The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: A large study from a single institution
(Cancer Research UK) Upcoming publication from the British Journal of Cancer, investigating HER2 expression as a predictor of recurrence and development in patients with DCIS. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 7, 2019 Category: Cancer & Oncology Source Type: news

Six Factors Tied to DCIS Returning as Breast Cancer Six Factors Tied to DCIS Returning as Breast Cancer
A group of six factors are associated with ductal carcinoma in situ returning as invasive breast cancer after treatment.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 25, 2019 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Six Prognostic Factors ID'd for Invasive Disease After DCIS
THURSDAY, April 25, 2019 -- In a review published online April 25 in Cancer Epidemiology, Biomarkers& Prevention, six prognostic factors are identified that may predict invasive disease after a diagnosis of ductal carcinoma in situ... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 25, 2019 Category: Pharmaceuticals Source Type: news

Six factors may predict invasive breast cancer recurrence after DCIS diagnosis
(American Association for Cancer Research) Six factors were associated with invasive recurrence of breast cancer after a diagnosis of ductal carcinoma in situ (DCIS), according to data from a meta-analysis. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 25, 2019 Category: Cancer & Oncology Source Type: news

Smart Biopsy Device Could Diagnose Breast Cancer Using Miniature Radiofrequency Sensors
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,” said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - March 12, 2019 Category: Medical Devices Authors: Susan Shepard Tags: Business Source Type: news

New diagnostic technique reveals a protein biomarker that accurately differentiates bladder cancer from benign inflammation
(Elsevier) Label-free digital pathology using infrared (IR) imaging with subsequent proteomic analysis for bladder cancer (BC) has revealed the first protein biomarker (AHNAK2) for BC. AHNAK2 differentiates between chronic cystitis (inflammation of the bladder) and a non-muscle invasive-type BC (carcinoma in situ) which is challenging to diagnose. A report in The American Journal of Pathology describes this new diagnostic procedure, which is label-free, automated, observer-independent, and as sensitive and specific as established histopathological methods. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2019 Category: Cancer & Oncology Source Type: news

Go Low With Tamoxifen for DCIS Go Low With Tamoxifen for DCIS
In a potentially practice-changing result, use of a 5-mg daily dose of tamoxifen for patients with ductal carcinoma in situ (DCIS) prevented new and recurrent breast cancer events in comparison with placebo.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 7, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Radiation therapy cuts low risk of recurrence by nearly 3/4 for patients with 'good risk'
(American Society for Radiation Oncology) A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservation surgery but can lower that risk even further with radiation therapy, finds a new long-term clinical trial report. These 12-year follow-up data from the only prospective, randomized trial to compare recurrence outcomes after treatment for low-risk ductal carcinoma in situ (DCIS) were presented last week at the 60th Annual Meeting of the American Society for Radiation Oncology (ASTRO). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - October 29, 2018 Category: Cancer & Oncology Source Type: news

Radiation Therapy Cuts Recurrence in'Good Risk' DCIS Radiation Therapy Cuts Recurrence in'Good Risk' DCIS
Whole-breast radiation halved the risk for recurrence in low-risk ductal carcinoma in situ (DCIS), but treatment after surgery needs to part of a physician-patient discussion.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Lumpectomy & #43; Radiation May Cut Breast Cancer Mortality in DCIS
MONDAY, Aug. 20, 2018 -- Treatment with lumpectomy and radiotherapy is associated with a reduction in breast cancer mortality versus lumpectomy or mastectomy alone among patients with ductal carcinoma in situ (DCIS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 20, 2018 Category: Pharmaceuticals Source Type: news

Lumpectomy Plus RT Tied to Lower Mortality in DCIS Lumpectomy Plus RT Tied to Lower Mortality in DCIS
Lumpectomy plus radiation is associated with a small but statistically significant reduced risk for breast cancer-related death compared to the other major options for ductal carcinoma in situ (DCIS).Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Association of radiation therapy plus lumpectomy in reduced risk of dying in women with DCIS
(JAMA Network) Lumpectomy plus radiation was associated with a small clinical benefit in reduced risk of breast cancer death compared with lumpectomy or mastectomy alone   in women   with ductal carcinoma in situ (DCIS), a noninvasive early form of breast cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 10, 2018 Category: Cancer & Oncology Source Type: news

Karl Storz Focuses on Bladder Cancer Detection With New Device
Karl Storz is focusing on bladder cancer detection with its latest product. The El Segunda, CA-based company said it is launching the PDD Blue Light Flexible Video Cytoscopy System. The product launch follows the approval of a supplemental new drug application and a premarket approval supplement from FDA extending the indication for Blue Light Cystoscopy with Cysview (BLCC) to include use of the new Karl Storz PDD Blue Light Flexible Video Cystoscope. Also included in the approval is an expanded indication for the repetitive use of Cysview within the same patient and for the identification of Carcinoma in Situ (CIS); one o...
Source: MDDI - May 18, 2018 Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news

Women With DCIS Who Are at Low Risk for Recurrence Identified Women With DCIS Who Are at Low Risk for Recurrence Identified
Women with ductal carcinoma in situ (DCIS) who are at low risk for disease recurrence after conservative breast surgery and radiotherapy, and whose treatment could be reduced, have been identified.Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 22, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Managing Ductal Carcinoma In Situ in the Era of Genomic Profiling
At the 2018 Miami Breast Cancer Conference, Dr. Patrick Borgen presented information related to gene expression profiling as a tool for managing DCIS. (Source: CancerNetwork)
Source: CancerNetwork - March 20, 2018 Category: Cancer & Oncology Authors: Patrick I. Borgen, MD Tags: Breast Cancer Conference Report Conferences/MBCC Source Type: news

Radioactive Seed Localization or Wire-guided Localization of Nonpalpable Invasive and In Situ Breast Cancer: A Randomized, Multicenter, Open-label Trial
This research article has led to a Practice Changing Update in DynaMed Plus. It concludes that radioactive seed localization may have similar positive margin but higher successful placement rates compared to wire localization in women having breast-conserving surgery for nonpalpable invasive breast cancer or ductal carcinoma in situ (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - January 18, 2018 Category: Consumer Health News Source Type: news

New cancer model shows genomic link between early-stage and invasive breast cancer types
(University of Texas M. D. Anderson Cancer Center) A new genetic-based model may explain how a common form of early-stage breast cancer known as ductal carcinoma in situ (DCIS) progresses to a more invasive form of cancer say researchers at The University of Texas MD Anderson Cancer Center. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 4, 2018 Category: Biology Source Type: news

Medical News Today: Carcinoma in situ: What is it and how is it treated?
In this article, learn about carcinoma in situ. What is carcinoma in situ and where does it occur? How is it most effectively treated? (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 26, 2017 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Local DCIS Recurrence After Skipping Adjuvant Radiation Local DCIS Recurrence After Skipping Adjuvant Radiation
Omitting radiation after lumpectomy for pure ductal carcinoma in situ (DCIS) does not improve the chance of breast preservation in case of local recurrence, researchers from Canada have observed.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 6, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

COUNTERPOINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
To universally recommend breast irradiation for all women after excision of DCIS lesions ignores information now available to us that can spare the majority of women with DCIS the downsides of RT, but be applied in the treatment of DCIS patients at greater risk for invasive disease. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: William C. Wood, MD Tags: Breast Cancer Oncology Journal Source Type: news

POINT: Should Radiation Therapy After Surgery for Ductal Carcinoma In Situ Be Standard Practice?
At this time RT following BCS remains the standard of care for most patients. Current tools, including prognostic scores and tumor genetics, have failed to identify a cohort for whom RT confers no benefit with respect to invasive recurrences. (Source: CancerNetwork)
Source: CancerNetwork - August 15, 2017 Category: Cancer & Oncology Authors: Camille Berriochoa, MD Carisa Bohnak, BS Chirag Shah, MD Nicole Chahine, BS Tags: Breast Cancer Oncology Journal Source Type: news

10 Facts Women Should Know About Endometrial Cancer
The most common cancer of the reproductive organs in American women is endometrial cancer. The American Cancer Society estimates that for the year 2017, around 61,380 new cases of cancer of the body of the uterus will be diagnosed and about 10,920 women will die from cancers of the uterine body. These figures include both endometrial cancers and uterine sarcomas. Since endometrial cancer is a fairly common cancer in women, the more women know the facts about this disease, the greater their chance of knowing what symptoms to be aware of in order to have it diagnosed as early as possible, improving the likelihood of surviva...
Source: Healthy Living - The Huffington Post - June 5, 2017 Category: Consumer Health News Source Type: news

Bilateral mastectomy not needed for DCIS
Women with ductal carcinoma in situ (DCIS) who choose bilateral mastectomy...Read more on AuntMinnie.comRelated Reading: How accurate are DCIS predictions from radiologists? Overdiagnosis claims not supported, ACR, SBI say ASTRO: Radiation boost cuts local recurrence in DCIS patients New treatment guidelines issued for DCIS Needle biopsy hormone testing unnecessary for DCIS (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 28, 2017 Category: Radiology Source Type: news

Why You Should Always Ask For A Second Opinion
Two years ago, when actress-singer Rita Wilson was 58, she underwent a double mastectomy and had this to say about it: Getting a second opinion saved her life. Wilson was right to insist on a second opinion, according to a Mayo Clinic study released this month. Of 286 patients who sought a second opinion from the clinic over a two-year period, 88 percent received a diagnosis that was either modified or completely different from the first one they received. Sixty-six percent of patients received a refined diagnosis and 22 percent received a completely different one, the study found.  Only 12 percent received confirmati...
Source: Healthy Living - The Huffington Post - April 26, 2017 Category: Consumer Health News Source Type: news